A four-protein expression prognostic signature predicts clinical outcome of lower-grade glioma

Patil, Vikas; Mahalingam, Kulandaivelu

doi:10.1016/j.gene.2018.08.001

Cited by 18 publications

(15 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The World Health Organization (WHO) classified gliomas into grades I–IV based on histological characteristics, which contained increased degrees of anaplasia, undifferentiation, and infiltration [ 3 ]. Diffuse low-grade (WHO grade II) and III intermediate-grade gliomas are called lower-grade gliomas (LGGs) [ 4 ]. Because of their rapid growth and highly remarkable aggressiveness, a subset of these LGGs will develop into glioblastoma (WHO grade IV) within several months [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Identification of collagen genes related to immune infiltration and epithelial-mesenchymal transition in glioma

Zhu²,

Tan

et al. 2021

Cancer Cell Int

View full text Add to dashboard Cite

Background Gliomas account for the majority of fatal primary brain tumors, and there is much room for research in the underlying pathogenesis, the multistep progression of glioma, and how to improve survival. In our study, we aimed to identify potential biomarkers or therapeutic targets of glioma and study the mechanism underlying the tumor progression. Methods We downloaded the microarray datasets (GSE43378 and GSE7696) from the Gene Expression Omnibus (GEO) database. Then, we used weighted gene co-expression network analysis (WGCNA) to screen potential biomarkers or therapeutic targets related to the tumor progression. ESTIMATE (Estimation of STromal and Immune cells in MAlignant Tumors using Expression data) algorithm and TIMER (Tumor Immune Estimation Resource) database were used to analyze the correlation between the selected genes and the tumor microenvironment. Real-time reverse transcription polymerase chain reaction was used to measure the selected gene. Transwell and wound healing assays were used to measure the cell migration and invasion capacity. Western blotting was used to test the expression of epithelial-mesenchymal transition (EMT) related markers. Results We identified specific module genes that were positively correlated with the WHO grade but negatively correlated with OS of glioma. Importantly, we identified that 6 collagen genes (COL1A1, COL1A2, COL3A1, COL4A1, COL4A2, and COL5A2) could regulate the immunosuppressive microenvironment of glioma. Moreover, we found that these collagen genes were significantly involved in the EMT process of glioma. Finally, taking COL3A1 as a further research object, the results showed that knockdown of COL3A1 significantly inhibited the migration, invasion, and EMT process of SHG44 and A172 cells. Conclusions In summary, our study demonstrated that collagen genes play an important role in regulating the immunosuppressive microenvironment and EMT process of glioma and could serve as potential therapeutic targets for glioma management.

show abstract

Section: Introductionmentioning

confidence: 99%

Identification of collagen genes related to immune infiltration and epithelial-mesenchymal transition in glioma

Zhu²,

Tan

et al. 2021

Cancer Cell Int

View full text Add to dashboard Cite

show abstract

“…Some LGGs tend to progress to WHO grade IV GBM within months, whereas others remain stable for years. The survival of patients with LGGs ranging from 1 to 15 years is closely related to therapeutic sensitivity (6). Because of high intraobserver and interobserver variability, the histopathological classification of…”

Section: Introductionmentioning

confidence: 99%

Development and Validation of a Tumor Mutation Burden–Related Immune Prognostic Model for Lower-Grade Glioma

Jiang

Tan

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Tumor mutation burden (TMB) is a useful biomarker to predict prognosis and the efficacy of immune checkpoint inhibitors (ICIs). In this study, we aimed to explore the prognostic value of TMB and the potential association between TMB and immune infiltration in lower-grade gliomas (LGGs). Somatic mutation and RNA-sequencing (RNA-seq) data were downloaded from the Cancer Genome Atlas (TCGA) database. TMB was calculated and patients were divided into high- and low-TMB groups. After performing differential analysis between high- and low-risk groups, we identified six hub TMB and immune-related genes that were correlated with overall survival in LGGs. Then, Gene Set Enrichment Analysis was performed to screen significantly enriched GO terms between the two groups. Moreover, an immune-related risk score system was developed by LASSO Cox analysis based on the six hub genes and was validated with the Chinese Glioma Genome Atlas dataset. Using the TIMER database, we further systematically analyzed the relationships between mutants of the six hub genes and immune infiltration levels, as well as the relationships between the immune-related risk score system and the immune microenvironment in LGGs. The results showed that TMB was negatively correlated with OS and high TMB might inhibit immune infiltration in LGGs. Furthermore, the risk score system could effectively stratify patients into low- and high-risk groups in both the training and validation datasets. Multivariate Cox analysis demonstrated that TMB was not an independent prognostic factor, but the risk score was. Higher infiltration of immune cells (B cells, CD4 + T cells, CD8 + T cells, neutrophils, macrophages, and dendritic cells) and higher levels of immune checkpoints (PD-1, CTLA-4, LAG-3, and TIM-3) were found in patients in the high-risk group. Finally, a novel nomogram model was constructed and evaluated to estimate the overall survival of LGG patients. In summary, our study provided new insights into immune infiltration in the tumor microenvironment and immunotherapies for LGGs.

show abstract

“…In recent years, despite substantial advances in treatment strategy, the rate of early diagnosis of glioma remains low and it is difficult to treat patients with late-stage glioma, thus leading to the relative low survival of this disease ( 108 ). Additionally, compared with other types of cancer, the overall prognosis of patients with glioma is worse and the survival period is shorter ( 109 ).…”

Section: Circrnas and Gliomamentioning

confidence: 99%

Circular RNA: A novel type of biomarker for glioma (Review)

et al. 2021

View full text Add to dashboard Cite

With the rapid development of sequencing technologies, the characteristics and functions of circular RNAs (circRNAs) in different tissues, and their underlying pathophysiological mechanisms, have been identified. circRNAs are significantly enriched in the brain and are continually expressed from the embryonic stage to the adult stage in rats. Previous studies have reported that certain circRNAs are differentially expressed in glioma and regulate a number of biological processes, such as cell proliferation, metastasis and oncogenesis of glioma. Furthermore, certain circRNAs have been associated with tumor size, World Health Organization tumor grade and poor prognosis in patients with glioma. It has been hypothesized that circRNAs may be involved in the onset and progression of glioma through transcriptional regulation, protein translation and binding to microRNAs. These properties and functions suggest the potential of circRNAs as prognostic biomarkers and therapeutic targets for glioma. For the present review, published studies were examined from PubMed, Embase, Cochrane Central and the reference lists of the retrieved articles. The aim of the present review was to summarize the progress of circRNA research in glioma, discuss the potential diagnostic and prognostic values, and the roles of circRNAs in glioma, and provide a novel theoretical basis and research concepts for the prediction, diagnosis and treatment of glioma.

show abstract

A four-protein expression prognostic signature predicts clinical outcome of lower-grade glioma

Cited by 18 publications

References 37 publications

Identification of collagen genes related to immune infiltration and epithelial-mesenchymal transition in glioma

Identification of collagen genes related to immune infiltration and epithelial-mesenchymal transition in glioma

Development and Validation of a Tumor Mutation Burden–Related Immune Prognostic Model for Lower-Grade Glioma

Circular RNA: A novel type of biomarker for glioma (Review)

Contact Info

Product

Resources

About